Rcop And Chop Case Studies

929 Words4 Pages
outcomes of regimens involving R-CHOP and CHOP. Incremental cost per life year saved and per year of quality adjusted life year saved was reported as outcomes from the US societal perspective. The costs as well as survival rate was discounted at 3% fixed annual rate (Hornberger, J. C., & Best, J. H. (2005). Clinical outcomes in this study resulted in 53% patients with event-free survival at 3 years in R-CHOP and 35% in CHOP. It is estimated that R-CHOP would increase the mean event-free survival from 2.19 years with CHOP to 3.10 years (additional 0.90 years) and overall survival with R-CHOP would increase from 3.11 years with CHOP to 4.15 years (additional 1.04 years). The mean cumulative cost of R-CHOP was $17,225 and that of CHOP was $3358,…show more content…
The study was conducted by developing a Markov model which included three health states (unprogressed, progressed and death). The results were concluded over a time horizon of 15 years. In the base case analysis, three treatments were compared that included three courses of first line treatment (Rituximab to fludarabine and cyclophosphamide) which was followed by three courses of post-progression salvage treatment with three courses of fludarabine and cyclophosphamide followed by three courses of salvage treatment excluding rituximab. The model also predicted that the patients received an average of two courses of treatments (Adena, M., Houltram, J., Mulligan, S. P., Todd, C., & Malanos, G.…show more content…
Patients treated with rituximab were observed to have increased survival as well as quality adjusted survival resulting in high value of utility and also low death rate. Treatment with rituximab furthermore delays the time period until patients require successive chronic lymphocytic leukemia. For patients with progressed and unprogressed states, utility scores were 0.805 and 0.618 respectively which was obtained by EQ-5D questionnaire. The incremental cost per quality of life gained associated with R-FC in patients who were previously untreated was found out to be A$36,131 which was lower than in relapsed/refractory patients (A$41,645). The use of rituximab in untreated patients was found to be more cost effective when compared to relapse/refractory patients. With the addition of rituximab, the incremental cost is A$40,268 and the cost per quality adjusted life year gained was found out to be A$42,906. There was also an incremental gain of 0.94 quality adjusted life years with the addition of rituximab. The model used various regimens throughout its study and concluded that rituximab is cost-effective in combination with chemotherapy for the treatment of chronic lymphocytic leukemia (Adena, M., Houltram, J., Mulligan, S. P., Todd, C., & Malanos, G.

More about Rcop And Chop Case Studies

Open Document